Carfilzomib 56 mg/m
2
twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment
Leukemia & Lymphoma | March 15, 2022 | Volume: 63 | Issue: 8 | Pages: 1887-1896
10.1080/10428194.2022.2047962
| PMID 35289710